Gut radiation may revive immunotherapy in resistant cancers
NCT ID NCT06076135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial investigates whether a single, low dose of radiation to the small intestine can help the immune system recognize and attack tumors again in people with advanced solid cancers that have stopped responding to immunotherapy. Participants receive 1Gy of radiation to the jejunum and ileum, followed by their previous or adjusted PD-1/PD-L1 inhibitor. The study aims to see if this combination can shrink tumors or slow disease progression, and it also collects blood and stool samples to explore why some patients respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiation to the intestine (1Gy) plus PD-1/PD-L1 inhibitors
What this could lead to
If successful, this approach could offer a new way to re-sensitize tumors that have stopped responding to immunotherapy, potentially improving outcomes for patients with advanced cancer.
What could go wrong
This is a small, early-phase trial (24 participants) and the combination may not work for everyone. There is also a risk of side effects from both radiation and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, 515031, China